Article Text

PDF
AB0931 Anti-TNF Agents in Intractable Familial Mediterranean Fever with Axial Spondylarthropathy: Four Cases
  1. M. Rozenbaum,
  2. L. Kaly,
  3. D. Rimar,
  4. G. Slobodin,
  5. N. Boulman,
  6. N. Jiries,
  7. I. Rosner
  1. Rheumatology, Bnai Zion Medical Center, HAIFA, Israel

Abstract

Background Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever and serositis. A relation between FMF and Ankylosing Spondylitis (AS) has been suggested in small cohort studies, although there is no consensus regarding the role of HLA B27. Colchicine, the mainstay treatment in FMF, does not improve the axial or peripheral symptoms due to spondylarthropathy. There are controversial data about the efficacy of Tumor Necrosis Factor Alpha (TNF α) blockade in FMF patients (1).

Objectives Efficacity of Tumor Necrosis Factor Alpha in FMF patients with axial spondyloarthropathy.

Methods We report our experience in 4 patients with intractable FMF treated with oral colchicine and supplemental IV colchicine (2), that were treated with TNF α blockade for symptomatic axial spondylarthropathy).

Results A 26- year-a old man with MEFV mutations V726A and E148Q, negative for HLAB27, with concomitant ulcerative colitis was treated with infliximab and then with adalimumab; and 3 women (42, 48 and 55 years old), two of them treated with infliximab and one treated with adalimumab. The three women were homozygous for the M694V mutation. All developed severe to moderate adverse events: exacerbation of FMF in 2 of them, and myositis and ulcerative colitis exacerbation in the male patient, and staphylococcus aureus sepsis in another patient. Three of them had to stop the TNF α blockade treatment. One patient developed psoriatic rash, with no need to stop the treatment.

Conclusions In our limited experience, TNF α blockade in patients with both intractable FMF and AS is not very effective and may be associated with severe adverse events. Little is known about the possible interaction between intravenous colchicine and anti-TNF treatment.

References

  1. Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, Ertenli I, Dogan I, Calguneri M. Effects of anti-tumor necrosis factors agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J clin Rheumatol 2011;7:358-62.

  2. Rozenbaum M, Boulman N, Feld J, Avshovich N, Petrovich S, Elias M, Slobodin G, Rosner I. Intravenous colchicine treatment for six months: adjunctive therapy in Familial Mediterranean fever (FMF) unresponsive to oral colchicine. Clin Exp Rheumatol 2009; 27 (2 suppl 53) S 105.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.1994

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.